Paraplegia Clinical Trials

Find Paraplegia Clinical Trials Near You

Rare Disease Registry Database for Movement Disorders in Southern Anhui Province

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

According to the World Health Organization (WHO) definition, a rare disease is a disease affecting fewer than 6.5 people per 10,000; in China, it generally refers to diseases with a prevalence of less than 1/10,000 (i.e., with a total of no more than 140,000 patients). Such diseases are mostly hereditary or congenital in origin. Patients with rare diseases often present with complex symptoms, most of which are neurological. Although a large number of rare diseases have been identified, the small number of patients with each disease and the diversity of symptoms make early diagnosis difficult and render large-sample clinical trials challenging. Consequently, most rare diseases lack curative treatments; available therapies are of limited efficacy or prohibitive cost, ultimately leading to severe disability or death and imposing a substantial socioeconomic burden. This study establishes a registry for motor neuron diseases (MND), spinocerebellar ataxias (SCAs), hereditary muscular dystrophy (HMD), and hereditary spastic paraplegia (HSP). Owing to the low incidence, complex clinical diagnosis, unclear pathogenic mechanisms, and strong genetic heterogeneity, epidemiological data on rare motor neuron diseases are limited, further increasing the difficulty of biomarker screening and targeted therapeutic development. Therefore, there is an urgent need to establish a comprehensive registry and to obtain reliable evidence on risk factors and early diagnosis through research. This study aims to establish a registry of rare neurological diseases in the southern Anhui Province and to build a high-quality biobank of human biological resources.

Eligibility
Participation Requirements
Sex: All
Healthy Volunteers: f
View:

• Adults aged 19 years or older who are capable of giving informed consent.

• Definitive diagnosis of one of the following diseases: (1) amyotrophic lateral sclerosis (diagnosed according to the revised El Escorial criteria, Awaji criteria, or Gold Coast criteria); (2) spinocerebellar ataxia; (3) muscular dystrophy; (4) hereditary spastic paraplegia.

• Others: primary lateral sclerosis, progressive muscular atrophy, ALS-FTD syndrome, progressive bulbar palsy, benign focal muscular atrophy, and other motor neuron diseases.

Locations
Other Locations
China
First affiliated hospital of Wannan Medical University
RECRUITING
Wuhu
Contact Information
Primary
Xianjin Shang, Prof.
shangxj2013@wnmc.edu.cn
86 151 5530 0503
Time Frame
Start Date: 2026-09-30
Estimated Completion Date: 2029-09
Participants
Target number of participants: 180
Treatments
Motor Neuron Diseases
Patient diagnosis, clinical assessment, treatment, and biological sample collection
spinocerebellar ataxia(SCAs)
Patient diagnosis, clinical assessment, treatment, and biological sample collection
hereditary muscular dystrophy
Patient diagnosis, clinical assessment, treatment, and biological sample collection
hereditary spastic paraplegia
Patient diagnosis, clinical assessment, treatment, and biological sample collection
Sponsors
Leads: First Affiliated Hospital of Wannan Medical College

This content was sourced from clinicaltrials.gov